Beneficial Effects of Statin Therapy on Survival in Hypertensive Patients With Acute Myocardial Infarction: Data From the RICO Survey

American Journal of Hypertension

Volumn 20, Issue 11, 2007, Pages 1133-1139

  Sicard, Pierre ^a,b   Zeller, Marianne ^a,b   Dentan, Gilles ^c   Laurent, Yves ^d   Touzery, Claude ^b   L'huillier, Isabelle ^b   Janin Manificat, Luc ^d   Lorgis, Luc ^b   Beer, Jean Claude ^b   Makki, Hamib ^d   Rochette, Luc ^a   Cottin, Yves ^b  

^a IFR Sante STIC   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c Clinique de Fontaine   (France)

^d Service de cardiologie   (France)

Author keywords

acute myocardial infarction; cohort study; Hypertension; statin

Indexed keywords

ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; STATINE DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; DATA COLLECTION; DATABASES, FACTUAL; FEMALE; FRANCE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; LIPIDS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 35349026176     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2007.05.006     Document Type: Article

References (28)

1. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., and Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
2. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 288 (2002) 2998-3007
3. Sicard P., Lauzier B., Oudot A., Busseuil D., Collin B., Duvillard L., Moreau D., Vergely C., and Rochette L. A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats. Arch Mal Coeur Vaiss 98 (2005) 804-808
4. Susic D., Varagic J., Ahn J., Slama M., and Frohlich E.D. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 42 (2003) 1091-1097
5. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 (2004) III39-III43
6. Haider A.W., Chen L., Larson M.G., Evans J.C., Chen M.H., and Levy D. Antecedent hypertension confers increased risk for adverse outcomes after initial myocardial infarction. Hypertension 30 (1997) 1020-1024
7. Herlitz J., Bang A., and Karlson B.W. Five-year prognosis after acute myocardial infarction in relation to a history of hypertension. Am J Hypertens 9 (1996) 70-76
8. Dumaine R., Gibson C.M., Murphy S.A., Southard M., Ly H.Q., McCabe C.H., Giugliano R.P., Cannon C.P., Antman E.M., and Braunwald E. Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich) 8 (2006) 315-322
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-1357
11. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., and Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
12. Zeller M., Steg P.G., Ravisy J., Laurent Y., Janin-Manificat L., L'Huillier I., Beer J.C., Oudot A., Rioufol G., Makki H., Farnier M., Rochette L., Verges B., and Cottin Y. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 165 (2005) 1192-1198
13. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
14. Seeger J.D., Walker A.M., Williams P.L., Saperia G.M., and Sacks F.M. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol 92 (2003) 1447-1451
15. Ferrieres J., Cambou J.P., Gueret P., Boutalbi Y., Lablanche J.M., Hanania G., Genes N., Cantet C., and Danchin N. Effect of early initiation of statins on survival in patients with acute myocardial infarction (the USIC 2000 Registry). Am J Cardiol 95 (2005) 486-489
16. Lenderink T., Boersma E., Gitt A.K., Zeymer U., Wallentin L., Van de Werf F., Hasdai D., Behar S., and Simoons M.L. Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J 27 (2006) 1799-1804
17. Stenestrand U., and Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 285 (2001) 430-436
18. Newby L.K., LaPointe N.M., Chen A.Y., Kramer J.M., Hammill B.G., DeLong E.R., Muhlbaier L.H., and Califf R.M. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113 (2006) 203-212
19. Spencer F.A., Allegrone J., Goldberg R.J., Gore J.M., Fox K.A., Granger C.B., Mehta R.H., and Brieger D. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 140 (2004) 857-866
20. Fonarow G.C., Wright R.S., Spencer F.A., Fredrick P.D., Dong W., Every N., and French W.J. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 96 (2005) 611-616
21. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
22. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
23. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., and Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
24. Newby L.K., Kristinsson A., Bhapkar M.V., Aylward P.E., Dimas A.P., Klein W.W., McGuire D.K., Moliterno D.J., Verheugt F.W., Weaver W.D., and Califf R.M. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 287 (2002) 3087-3095
25. Calabro P., and Yeh E.T. The pleiotropic effects of statins. Curr Opin Cardiol 20 (2005) 541-546
26. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
27. Danchin N., Grenier O., Ferrieres J., Cantet C., and Cambou J.P. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart 88 (2002) 159-162
28. Aronow H.D., Novaro G.M., Lauer M.S., Brennan D.M., Lincoff A.M., Topol E.J., Kereiakes D.J., and Nissen S.E. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med 163 (2003) 2576-2582